

Christopher E Nelson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6426405/publications.pdf>

Version: 2024-02-01

11
papers

1,903
citations

932766

10
h-index

1281420

11
g-index

12
all docs

12
docs citations

12
times ranked

3440
citing authors

#	ARTICLE	IF	CITATIONS
1	In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. <i>Science</i> , 2016, 351, 403-407.	6.0	957
2	Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. <i>Nature Medicine</i> , 2019, 25, 427-432.	15.2	303
3	RNA-guided transcriptional silencing in vivo with <i>S. aureus</i> CRISPR-Cas9 repressors. <i>Nature Communications</i> , 2018, 9, 1674.	5.8	123
4	Engineering Delivery Vehicles for Genome Editing. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2016, 7, 637-662.	3.3	93
5	AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. <i>JCI Insight</i> , 2018, 3, .	2.3	79
6	Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells. <i>Nature Biotechnology</i> , 2019, 37, 1493-1501.	9.4	73
7	Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. <i>Nature Communications</i> , 2021, 12, 6769.	5.8	73
8	MiRNA inhibition in tissue engineering and regenerative medicine. <i>Advanced Drug Delivery Reviews</i> , 2015, 88, 123-137.	6.6	72
9	Genome engineering: a new approach to gene therapy for neuromuscular disorders. <i>Nature Reviews Neurology</i> , 2017, 13, 647-661.	4.9	68
10	Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. <i>Nature Communications</i> , 2017, 8, 15999.	5.8	53
11	Cas9 loosens its grip on off-target sites. <i>Nature Biotechnology</i> , 2016, 34, 299-299.	9.4	9